Compare · AUTL vs XBIO
AUTL vs XBIO
Side-by-side comparison of Autolus Therapeutics plc (AUTL) and Xenetic Biosciences Inc. (XBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AUTL focuses on Biotechnology: Biological Products (No Diagnostic Substances), while XBIO focuses on Biotechnology: Pharmaceutical Preparations.
- AUTL is the larger of the two at $261.0M, about 72.3x XBIO ($3.6M).
- AUTL has been more active in the news (13 items in the past 4 weeks vs 6 for XBIO).
- AUTL has more recent analyst coverage (7 ratings vs 0 for XBIO).
- Company
- Autolus Therapeutics plc
- Xenetic Biosciences Inc.
- Price
- -
- -
- Market cap
- $261.0M
- $3.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 13
- 6
- Recent ratings
- 7
- 0
Autolus Therapeutics plc
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
Xenetic Biosciences Inc.
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. The company is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Latest AUTL
- Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc
- SEC Form S-8 filed by Autolus Therapeutics plc
- Amendment: SEC Form SCHEDULE 13G/A filed by Autolus Therapeutics plc
- SEC Form 10-Q filed by Autolus Therapeutics plc
- Amendment: SEC Form SCHEDULE 13D/A filed by Autolus Therapeutics plc
- Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
- Autolus Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Autolus Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
- Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2026
Latest XBIO
- SEC Form DEFA14A filed by Xenetic Biosciences Inc.
- Xenetic Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates
- SEC Form 10-Q filed by Xenetic Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Xenetic Biosciences Inc.
- Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance
- Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma
- Xenetic Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Xenetic Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics